{"success":true,"data":{"pressRelease":{"id":"155128","rtpr_id":"nACSVBXJJa-20260929","ticker":"AIML","exchange":"","all_tickers":["AIML"],"title":"AIML Subsidiary NeuralCloud Enters Strategic Partnership with RKS Medical Technologies to Advance CardioYield(TM) Clinical Pilots","author":"ACCESSWIRE","published_at":"2026-09-29T11:30:00.313Z","article_body":"TORONTO, ON / ACCESS Newswire (https://www.accessnewswire.com/) / September\n29, 2026 / AI/ML Innovations Inc. (\"AIML\" or the \"Company\")\n(CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence\nand neural-network-based technologies for digital health, is pleased to\nannounce that its wholly owned subsidiary, NeuralCloud Solutions Inc.\n(\"NeuralCloud\"), has entered into a strategic partnership with RKS Medical\nTechnologies (\"RKS Medical\"), a Toronto-based medical technology company, to\nsupport clinical pilot deployments of NeuralCloud's CardioYield(™) software\nplatform with RKS Medical's myPatch(®) Holter monitoring technology.\n\nRKS Medical, a leading M&A advisory firm in the diagnostic imaging sector also\ncommercializes medical equipment and healthcare technology solutions across\nCanada and is the exclusive Canadian reseller of the myPatch(®)SL wireless\nHolter recorder. The myPatch(®)SL device is designed for patient and provider\nease, offering lightweight, waterproof Holter monitoring with up to three\nchannels of continuous ECG, multiple electrode size options, event markers, an\ninternal clock, rechargeable battery, and compatibility with major Holter\nanalysis systems.\n\nUnder the partnership, RKS Medical is expected to introduce NeuralCloud to\nclinics using, or evaluating, myPatch(®) technology in order to conduct\npre-regulatory clearance pilot evaluations of CardioYield(™). The objective\nis to evaluate how CardioYield(™) can support clinics by providing a\nsoftware layer for enhanced ECG signal review, automated waveform analysis,\nreport preparation, and workflow efficiency using ECG recordings captured\nthrough myPatch(®) devices.\n\nCreating an Integrated Hardware and Software Workflow\n\nThe partnership is designed to create a more complete cardiac monitoring\nsolution for clinics by pairing myPatch(®) hardware with NeuralCloud's\nCardioYield(™) software. myPatch(®) provides the ECG recording hardware,\nwhile CardioYield(™) is intended to provide the software intelligence layer\nfor reviewing and analyzing Holter recordings.\n\nCardioYield(™) is NeuralCloud's visualization and reporting platform powered\nby MaxYield(™), its proprietary ECG signal-processing engine. MaxYield(™)\nis designed to improve ECG signal quality, isolate and label key waveform\ncomponents - including P waves, QRS complexes, and T waves - and extract\nbeat-level interval data. CardioYield(™) builds on those outputs by\nproviding a user interface for reviewing enhanced Holter signals, highlighting\nPQRST intervals and morphology, grouping conditions and abnormalities, and\ngenerating structured Holter reports designed to support clinical workflow.\n\nEsmat Naikyar, President of NeuralCloud Solutions Inc. and Chief Product\nOfficer of AIML, commented: \"Clinics need cardiac monitoring solutions that\nare accurate, efficient, and practical to deploy. RKS Medical's myPatch\nplatform provides a flexible Holter recording option, and CardioYield is\ndesigned to add the software layer needed to transform ECG recordings into\ncleaner, structured, and more actionable outputs. This partnership gives us a\npathway to evaluate the combined workflow in real clinical environments.\"\n\nClinical Pilot Strategy\n\nThe initial focus of the partnership will be clinical pilot programs in\nOntario, with potential expansion to additional Canadian provinces. RKS\nMedical is expected to help identify and introduce clinic sites, while\nNeuralCloud will run the CardioYield pilots directly and handle clinical\nintegration.\n\nThe pilot framework is expected to use de-identified ECG recordings captured\nthrough myPatch(®) devices during normal care. The same ECG files are\nexpected to be routed through both the clinic's existing workflow and\nCardioYield™ for side-by-side evaluation, allowing the parties to assess\ndifferences attributable to the software workflow.\n\nPilot evaluations are expected to assess physician-ready report agreement,\nfalse positives and false negatives, technician edit time, time to report,\nreport quality, turnaround time, usability, total analyzable signal, artifact\ndetection, signal-quality scoring, and detection of certain rhythm categories.\n\nPaul Duffy, Executive Chairman and CEO of AIML, added: \"This partnership is\nabout demonstrating CardioYield in the workflow where it matters: real\nclinics, real Holter files, and real operational constraints. By working with\nRKS Medical and myPatch, we can evaluate CardioYield alongside an established\nHolter recording platform and show clinics how advanced ECG software may help\nimprove throughput, signal quality, and reporting efficiency.\"\n\nCommercialization Strategy\n\nThe partnership reflects NeuralCloud's broader strategy to build a network of\nclinical pilot sites and hardware partners ahead of future commercial\ndeployment. By pairing CardioYield(™) with myPatch(®) technology, the\nCompany's objective is to offer clinics an integrated hardware-and-software\npathway for Holter monitoring: one source recording, enhanced signal\nprocessing, structured review, and report generation.\n\nRalph Schatzmair, President of RKS Medical Technologies, commented: \"RKS\nMedical is focused on bringing practical medical technologies to Canadian\nhealthcare providers. By working with NeuralCloud, we see an opportunity to\nevaluate an integrated myPatch and CardioYield workflow that may support\nclinics seeking efficient, high-quality Holter monitoring solutions.\"\n\nCardioYield(™) has not received Health Canada or FDA clearance and is not\ncurrently authorized for diagnostic use. The proposed pilots are expected to\nbe conducted as pre-regulatory clearance evaluations. During any pilot, the\nclinic's existing systems and qualified healthcare professionals will remain\nresponsible for official reports, clinical interpretation, and all\npatient-care decisions. Nothing in the pilots or related evaluations\nconstitutes a claim of Health Canada or FDA clearance, approval, or\nauthorization for CardioYield(™).\n\nNovember 2024 Financing - Warrant Expiry Date Extension\n\nThe Company also announces that it has approved the extension of the expiry\ndate of an aggregate of 44,189,076 existing share purchase warrants which were\nissued on November 1, 2024 and November 26, 2024 (the \"November 2024\nWarrants\") in conjunction with a non-brokered private placement of units at a\nprice of $0.065 per unit (the \"November 2024 Financing\"). Each November 2024\nWarrant is exercisable to acquire one common share of the Company at an\nexercise price of $0.15. The original expiry dates of the November 2024\nWarrants are November 1, 2026, in respect of 19,688,461 November 2024\nWarrants, and November 26, 2026, in respect of 24,500,615 November 2024\nWarrants. The new expiry dates of the November 2024 Warrants are November 1,\n2029 and November 26, 2029, respectively, a period of five (5) years from the\napplicable issuance date.\n\nAll other terms and conditions of the November 2024 Warrants remain unchanged.\nThe Company notes that pursuant to CSE Policy 6.7(3), amendments related to\nbroker warrants are not permitted and as such there is no extension to the\nbroker warrants issued in conjunction with the November 2024 Financing. For\nfurther details with respect to the November 2024 Warrants or the November\n2024 Financing, please refer to the press releases of the Company dated\nNovember 1, 2024 and November 26, 2024 available on SEDAR+ at\nwww.sedarplus.ca.\n\nAbout RKS Medical Technologies\n\nRKS Medical Technologies is a Toronto-based medical technology company that\ncommercializes, implements, and supports medical equipment and healthcare\ntechnology solutions for Canadian healthcare providers. RKS Medical offers\nmyPatch(®)SL, a wireless Holter recorder designed to support ambulatory ECG\nmonitoring with a lightweight, waterproof form factor, up to three channels of\ncontinuous ECG, and compatibility with major Holter analysis systems. In\naddition to its medical technology business, RKS Medical provides M&A advisory\nservices to diagnostic imaging clinics and other healthcare organizations\nacross Canada.\n\nFor more information please see RKS Medical's website at www.rksmedical.com.\n\nAbout AI/ML Innovations Inc.\n\nAIML Innovations Inc. is a global technology company pioneering the use of\nartificial intelligence and neural networks to transform digital health. Our\nproprietary platforms leverage advanced signal processing and deep learning to\nconvert complex biometric data into actionable clinical insights - supporting\nearlier diagnosis, personalized treatment, and more effective care.\n\nAIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB\nVenture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).\n\nFor detailed information please see AIML's website at https://www.aiml.health\nor the Company's filed documents at www.sedarplus.ca.\n\nAIML Contact:\n\nPaul Duffy, Executive Chairman and CEO\nask@aiml-innovations.com\n416-941-8900\n\nNeither the CSE nor its Regulation Services Provider (as that term is defined\nin the policies of the CSE) accepts responsibility for the adequacy or\naccuracy of this release.\n\nForward Looking Statements - Certain information set forth in this news\nrelease may contain forward-looking statements that involve substantial known\nand unknown risks and uncertainties, including risks associated with the\nimplementation of the Company's products and services as currently proposed or\nat all. Forward-looking statements in this news release include, without\nlimitation, statements regarding the anticipated clinical pilot programs, the\nCompany's objectives for an integrated myPatch(®) and CardioYield(™)\nworkflow, and the potential benefits to clinics of such workflow. There can be\nno assurance that the pilots will be completed or successful, that\nCardioYield(™) will receive regulatory clearance, or that clinics will\nrealize any of the intended benefits. These forward-looking statements are\nsubject to numerous risks and uncertainties, certain of which are beyond the\ncontrol of the Company, including with respect to the nature and timing of\nfuture operations and the receipt of all applicable regulatory approvals.\nReaders are cautioned that the assumptions used in the preparation of such\ninformation, although considered reasonable at the time of preparation, may\nprove to be imprecise and, as such, undue reliance should not be placed on\nforward-looking statements.\n\nSOURCE: AI/ML Innovations Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/publishing-and-media/aiml-subsidiary-neuralcloud-enters-strategic-partnership-with-rks-medical-tech-1228306)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSVBXJJa-20260929","title":"AIML Subsidiary NeuralCloud Enters Strategic Partnership with RKS Medical Technologies to Advance CardioYield(TM) Clinical Pilots","author":"ACCESSWIRE","ticker":"AIML","created":"2026-09-29T11:30:00.313Z","tickers":["AIML"],"exchange":"","article_body":"TORONTO, ON / ACCESS Newswire (https://www.accessnewswire.com/) / September\n29, 2026 / AI/ML Innovations Inc. (\"AIML\" or the \"Company\")\n(CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence\nand neural-network-based technologies for digital health, is pleased to\nannounce that its wholly owned subsidiary, NeuralCloud Solutions Inc.\n(\"NeuralCloud\"), has entered into a strategic partnership with RKS Medical\nTechnologies (\"RKS Medical\"), a Toronto-based medical technology company, to\nsupport clinical pilot deployments of NeuralCloud's CardioYield(™) software\nplatform with RKS Medical's myPatch(®) Holter monitoring technology.\n\nRKS Medical, a leading M&A advisory firm in the diagnostic imaging sector also\ncommercializes medical equipment and healthcare technology solutions across\nCanada and is the exclusive Canadian reseller of the myPatch(®)SL wireless\nHolter recorder. The myPatch(®)SL device is designed for patient and provider\nease, offering lightweight, waterproof Holter monitoring with up to three\nchannels of continuous ECG, multiple electrode size options, event markers, an\ninternal clock, rechargeable battery, and compatibility with major Holter\nanalysis systems.\n\nUnder the partnership, RKS Medical is expected to introduce NeuralCloud to\nclinics using, or evaluating, myPatch(®) technology in order to conduct\npre-regulatory clearance pilot evaluations of CardioYield(™). The objective\nis to evaluate how CardioYield(™) can support clinics by providing a\nsoftware layer for enhanced ECG signal review, automated waveform analysis,\nreport preparation, and workflow efficiency using ECG recordings captured\nthrough myPatch(®) devices.\n\nCreating an Integrated Hardware and Software Workflow\n\nThe partnership is designed to create a more complete cardiac monitoring\nsolution for clinics by pairing myPatch(®) hardware with NeuralCloud's\nCardioYield(™) software. myPatch(®) provides the ECG recording hardware,\nwhile CardioYield(™) is intended to provide the software intelligence layer\nfor reviewing and analyzing Holter recordings.\n\nCardioYield(™) is NeuralCloud's visualization and reporting platform powered\nby MaxYield(™), its proprietary ECG signal-processing engine. MaxYield(™)\nis designed to improve ECG signal quality, isolate and label key waveform\ncomponents - including P waves, QRS complexes, and T waves - and extract\nbeat-level interval data. CardioYield(™) builds on those outputs by\nproviding a user interface for reviewing enhanced Holter signals, highlighting\nPQRST intervals and morphology, grouping conditions and abnormalities, and\ngenerating structured Holter reports designed to support clinical workflow.\n\nEsmat Naikyar, President of NeuralCloud Solutions Inc. and Chief Product\nOfficer of AIML, commented: \"Clinics need cardiac monitoring solutions that\nare accurate, efficient, and practical to deploy. RKS Medical's myPatch\nplatform provides a flexible Holter recording option, and CardioYield is\ndesigned to add the software layer needed to transform ECG recordings into\ncleaner, structured, and more actionable outputs. This partnership gives us a\npathway to evaluate the combined workflow in real clinical environments.\"\n\nClinical Pilot Strategy\n\nThe initial focus of the partnership will be clinical pilot programs in\nOntario, with potential expansion to additional Canadian provinces. RKS\nMedical is expected to help identify and introduce clinic sites, while\nNeuralCloud will run the CardioYield pilots directly and handle clinical\nintegration.\n\nThe pilot framework is expected to use de-identified ECG recordings captured\nthrough myPatch(®) devices during normal care. The same ECG files are\nexpected to be routed through both the clinic's existing workflow and\nCardioYield™ for side-by-side evaluation, allowing the parties to assess\ndifferences attributable to the software workflow.\n\nPilot evaluations are expected to assess physician-ready report agreement,\nfalse positives and false negatives, technician edit time, time to report,\nreport quality, turnaround time, usability, total analyzable signal, artifact\ndetection, signal-quality scoring, and detection of certain rhythm categories.\n\nPaul Duffy, Executive Chairman and CEO of AIML, added: \"This partnership is\nabout demonstrating CardioYield in the workflow where it matters: real\nclinics, real Holter files, and real operational constraints. By working with\nRKS Medical and myPatch, we can evaluate CardioYield alongside an established\nHolter recording platform and show clinics how advanced ECG software may help\nimprove throughput, signal quality, and reporting efficiency.\"\n\nCommercialization Strategy\n\nThe partnership reflects NeuralCloud's broader strategy to build a network of\nclinical pilot sites and hardware partners ahead of future commercial\ndeployment. By pairing CardioYield(™) with myPatch(®) technology, the\nCompany's objective is to offer clinics an integrated hardware-and-software\npathway for Holter monitoring: one source recording, enhanced signal\nprocessing, structured review, and report generation.\n\nRalph Schatzmair, President of RKS Medical Technologies, commented: \"RKS\nMedical is focused on bringing practical medical technologies to Canadian\nhealthcare providers. By working with NeuralCloud, we see an opportunity to\nevaluate an integrated myPatch and CardioYield workflow that may support\nclinics seeking efficient, high-quality Holter monitoring solutions.\"\n\nCardioYield(™) has not received Health Canada or FDA clearance and is not\ncurrently authorized for diagnostic use. The proposed pilots are expected to\nbe conducted as pre-regulatory clearance evaluations. During any pilot, the\nclinic's existing systems and qualified healthcare professionals will remain\nresponsible for official reports, clinical interpretation, and all\npatient-care decisions. Nothing in the pilots or related evaluations\nconstitutes a claim of Health Canada or FDA clearance, approval, or\nauthorization for CardioYield(™).\n\nNovember 2024 Financing - Warrant Expiry Date Extension\n\nThe Company also announces that it has approved the extension of the expiry\ndate of an aggregate of 44,189,076 existing share purchase warrants which were\nissued on November 1, 2024 and November 26, 2024 (the \"November 2024\nWarrants\") in conjunction with a non-brokered private placement of units at a\nprice of $0.065 per unit (the \"November 2024 Financing\"). Each November 2024\nWarrant is exercisable to acquire one common share of the Company at an\nexercise price of $0.15. The original expiry dates of the November 2024\nWarrants are November 1, 2026, in respect of 19,688,461 November 2024\nWarrants, and November 26, 2026, in respect of 24,500,615 November 2024\nWarrants. The new expiry dates of the November 2024 Warrants are November 1,\n2029 and November 26, 2029, respectively, a period of five (5) years from the\napplicable issuance date.\n\nAll other terms and conditions of the November 2024 Warrants remain unchanged.\nThe Company notes that pursuant to CSE Policy 6.7(3), amendments related to\nbroker warrants are not permitted and as such there is no extension to the\nbroker warrants issued in conjunction with the November 2024 Financing. For\nfurther details with respect to the November 2024 Warrants or the November\n2024 Financing, please refer to the press releases of the Company dated\nNovember 1, 2024 and November 26, 2024 available on SEDAR+ at\nwww.sedarplus.ca.\n\nAbout RKS Medical Technologies\n\nRKS Medical Technologies is a Toronto-based medical technology company that\ncommercializes, implements, and supports medical equipment and healthcare\ntechnology solutions for Canadian healthcare providers. RKS Medical offers\nmyPatch(®)SL, a wireless Holter recorder designed to support ambulatory ECG\nmonitoring with a lightweight, waterproof form factor, up to three channels of\ncontinuous ECG, and compatibility with major Holter analysis systems. In\naddition to its medical technology business, RKS Medical provides M&A advisory\nservices to diagnostic imaging clinics and other healthcare organizations\nacross Canada.\n\nFor more information please see RKS Medical's website at www.rksmedical.com.\n\nAbout AI/ML Innovations Inc.\n\nAIML Innovations Inc. is a global technology company pioneering the use of\nartificial intelligence and neural networks to transform digital health. Our\nproprietary platforms leverage advanced signal processing and deep learning to\nconvert complex biometric data into actionable clinical insights - supporting\nearlier diagnosis, personalized treatment, and more effective care.\n\nAIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB\nVenture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).\n\nFor detailed information please see AIML's website at https://www.aiml.health\nor the Company's filed documents at www.sedarplus.ca.\n\nAIML Contact:\n\nPaul Duffy, Executive Chairman and CEO\nask@aiml-innovations.com\n416-941-8900\n\nNeither the CSE nor its Regulation Services Provider (as that term is defined\nin the policies of the CSE) accepts responsibility for the adequacy or\naccuracy of this release.\n\nForward Looking Statements - Certain information set forth in this news\nrelease may contain forward-looking statements that involve substantial known\nand unknown risks and uncertainties, including risks associated with the\nimplementation of the Company's products and services as currently proposed or\nat all. Forward-looking statements in this news release include, without\nlimitation, statements regarding the anticipated clinical pilot programs, the\nCompany's objectives for an integrated myPatch(®) and CardioYield(™)\nworkflow, and the potential benefits to clinics of such workflow. There can be\nno assurance that the pilots will be completed or successful, that\nCardioYield(™) will receive regulatory clearance, or that clinics will\nrealize any of the intended benefits. These forward-looking statements are\nsubject to numerous risks and uncertainties, certain of which are beyond the\ncontrol of the Company, including with respect to the nature and timing of\nfuture operations and the receipt of all applicable regulatory approvals.\nReaders are cautioned that the assumptions used in the preparation of such\ninformation, although considered reasonable at the time of preparation, may\nprove to be imprecise and, as such, undue reliance should not be placed on\nforward-looking statements.\n\nSOURCE: AI/ML Innovations Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/publishing-and-media/aiml-subsidiary-neuralcloud-enters-strategic-partnership-with-rks-medical-tech-1228306)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-09-29T11:30:01.957599497Z","server_sent_at_ms":1790681401957},"received_at":"2026-09-29T11:30:02.044Z","source_url":"https://www.accessnewswire.com/newsroom/en/publishing-and-media/aiml-subsidiary-neuralcloud-enters-strategic-partnership-with-rks-medical-tech-1228306"},"analysis":{"id":"143872","press_release_id":"155128","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["CardioYield has no Health Canada or FDA clearance and is not authorized for diagnostic use","pilots are pre-regulatory; no assurance pilots complete successfully or lead to commercialization","large outstanding warrant overhang: 44.2M warrants at $0.15 exercise, now extended to 2029"],"eventType":"partnership","narrative":"AIML's wholly owned subsidiary NeuralCloud entered a strategic partnership with RKS Medical Technologies to run clinical pilots pairing CardioYield software with RKS's myPatch Holter hardware, initially in Ontario clinics.\n\nCardioYield has not received Health Canada or FDA clearance and the pilots are explicitly pre-regulatory evaluations; clinics' existing systems remain responsible for official reports.\n\nSeparately, AIML extended the expiry of 44,189,076 November 2024 warrants ($0.15 exercise price) by five years to November 2029, reducing near-term warrant-expiry pressure.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Micro-cap AI health firm lines up Canadian clinical pilots for uncleared CardioYield software; early-stage with no revenue visibility."},"keyFigures":{"customDimensions":{"warrants_extended":44189076,"warrant_exercise_price":"$0.15","new_warrant_expiry_dates":["November 1, 2029","November 26, 2029"],"original_warrant_expiry_dates":["November 1, 2026","November 26, 2026"]}},"quotedText":"This partnership is about demonstrating CardioYield in the workflow where it matters: real clinics, real Holter files, and real operational constraints.","namedEntities":{"people":[{"name":"Esmat Naikyar","role":"President of NeuralCloud Solutions Inc. and Chief Product Officer of AIML"},{"name":"Paul Duffy","role":"Executive Chairman and CEO of AIML"},{"name":"Ralph Schatzmair","role":"President of RKS Medical Technologies"}],"products":["CardioYield(TM)","MaxYield(TM)","myPatch(R)","myPatch(R)SL"],"companies":[{"name":"AI/ML Innovations Inc.","ticker":"AIML","relationship":"filer/parent"},{"name":"NeuralCloud Solutions Inc.","relationship":"wholly owned subsidiary of AIML"},{"name":"RKS Medical Technologies","relationship":"partner"}],"dollarAmounts":[{"amount":"$0.065","context":"per-unit price of November 2024 non-brokered private placement"},{"amount":"$0.15","context":"exercise price of November 2024 Warrants"}]},"materialImpact":{"score":2,"reasoning":"Pre-revenue micro-cap announces a non-binding clinical pilot partnership for CardioYield, which has no Health Canada or FDA clearance; revenue impact is speculative and distant. A warrant expiry extension to 2029 is administrative."},"tickerRelevance":{"others":[{"ticker":"AIMLF","relevance":"OTCQB listing of filer"},{"ticker":"42FB","relevance":"Frankfurt listing of filer"}],"primary":"AIML"},"globalImportance":12,"audienceRelevance":8,"eventTypeSecondary":["other"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"pre-commercial pilot partnership","regulatoryStatus":"no clearance","warrantExtension":"administrative"}},"event_type":"partnership","event_type_secondary":["other"],"sentiment":"bullish","material_impact_score":2,"narrative":"AIML's wholly owned subsidiary NeuralCloud entered a strategic partnership with RKS Medical Technologies to run clinical pilots pairing CardioYield software with RKS's myPatch Holter hardware, initially in Ontario clinics.\n\nCardioYield has not received Health Canada or FDA clearance and the pilots are explicitly pre-regulatory evaluations; clinics' existing systems remain responsible for official reports.\n\nSeparately, AIML extended the expiry of 44,189,076 November 2024 warrants ($0.15 exercise price) by five years to November 2029, reducing near-term warrant-expiry pressure.","key_figures":{"customDimensions":{"warrants_extended":44189076,"warrant_exercise_price":"$0.15","new_warrant_expiry_dates":["November 1, 2029","November 26, 2029"],"original_warrant_expiry_dates":["November 1, 2026","November 26, 2026"]}},"named_entities":{"people":[{"name":"Esmat Naikyar","role":"President of NeuralCloud Solutions Inc. and Chief Product Officer of AIML"},{"name":"Paul Duffy","role":"Executive Chairman and CEO of AIML"},{"name":"Ralph Schatzmair","role":"President of RKS Medical Technologies"}],"products":["CardioYield(TM)","MaxYield(TM)","myPatch(R)","myPatch(R)SL"],"companies":[{"name":"AI/ML Innovations Inc.","ticker":"AIML","relationship":"filer/parent"},{"name":"NeuralCloud Solutions Inc.","relationship":"wholly owned subsidiary of AIML"},{"name":"RKS Medical Technologies","relationship":"partner"}],"dollarAmounts":[{"amount":"$0.065","context":"per-unit price of November 2024 non-brokered private placement"},{"amount":"$0.15","context":"exercise price of November 2024 Warrants"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T11:30:09.745Z","global_importance":12,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap","eventGravity":"pre-commercial pilot partnership","regulatoryStatus":"no clearance","warrantExtension":"administrative"}},"durationMs":7663,"modelName":"glm-5.3-flashx"}}